Linked Life Data

15675573

Source:http://linkedlifedata.com/resource/pubmed/id/15675573

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-1-28
pubmed:abstractText
The choice of second-line chemotherapy for malignant lymphoma in cases of both Hodgkin lymphoma and non-Hodgkin lymphoma depends on the results of first-line therapies. However, the trends in first-line therapy for malignant lymphoma have undergone significant changes over the last few years. The change has resulted from three facts: 1) the concept of dose intensity had to be revised, 2) newly-found prognostic factors have shown the need for therapy that takes risk grouping into consideration, and 3) new therapies, such as immunotherapy using monoclonal antibodies, have emerged. Based on these recent trends, this paper describes salvage therapies as a "recommendation" or "guideline" for cases of relapse or therapy-resistant disease which involve standard therapeutic measures.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
32
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6-10
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
[The choice of second-line chemotherapy for malignant lymphoma].
pubmed:affiliation
Dept. of Hematology, Oncology and Rheumatology, Tokai University School of Medicine, Boseidai Isehara city, Kanagawa 259-1193, Japan.
pubmed:publicationType
Journal Article, English Abstract